Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Reactive oxygen comes of age: Mechanism-based therapy of diabetic end-organ damage

  • Elbatreek, Mahmoud H.
  • Pachado, Mayra P.
  • Cuadrado, Antonio
  • Jandeleit-Dahm, Karin
  • Schmidt, Harald H.H.W.
Reactive oxygen species (ROS) have been mainly viewed as unwanted by-products of cellular metabolism, oxidative stress, a sign of a cellular redox imbalance, and potential disease mechanisms, such as in diabetes mellitus (DM). Antioxidant therapies, however, have failed to provide clinical benefit. This paradox can be explained by recent discoveries that ROS have mainly essential signaling and metabolic functions and evolutionally conserved physiological enzymatic sources. Disease can occur when ROS accumulate in nonphysiological concentrations, locations, or forms. By focusing on disease-relevant sources and targets of ROS, and leaving ROS physiology intact, precise therapeutic interventions are now possible and are entering clinical trials. Their outcomes are likely to profoundly change our concepts of ROS in DM and in medicine in general., H.H.H.W.S. wishes to gratefully acknowledge funding by an ERC Advanced Investigator Grant (294683 – RadMed), an ERC proof-of-concept grant (139-101052 – SAVEBRAIN), and the EU Horizon 2020 programme, REPO-TRIAL. K.J.D. is supported by a fellowship of the National Health and Medical Research Council. A.C. is the recipient of grant SAF2016-76520-R from the Spanish Ministry of Economy and Competitiveness, P_37_732/2016 REDBRAIN from the European Regional Development Fund, and the Competitiveness Operational Program 2014-2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

On the clinical pharmacology of reactive oxygen species

  • Casas, Ana I.
  • Nogales, Cristian
  • Mucke, Hermann A. M.
  • Petraina, Alexandra
  • Cuadrado, Antonio
  • Rojo, Ana I.
  • Ghezzi, Pietro
  • Jaquet, Vincent
  • Augsburger, Fiona
  • Dufrasne, Francois
  • Soubhye, Jalal
  • Deshwal, Soni
  • Di Sante, Moises
  • Kaludercic, Nina
  • Di Lisa, Fabio
  • Schmidt, Harald H.H.W.
Rhian M. Touyz, Associate Editor, Reactive oxygen species (ROS) have been correlated with almost every human disease. Yet clinical exploitation of these hypotheses by pharmacological modulation of ROS has been scarce to nonexistent. Are ROS, thus, irrelevant for disease? No. One key misconception in the ROS field has been its consideration as a rather detrimental metabolic by-product of cell metabolism, and thus, any approach eliminating ROS to a certain tolerable level would be beneficial. We now know, instead, that ROS at every concentration, low or high, can serve many essential signaling and metabolic functions. This likely explains why systemic, nonspecific antioxidants have failed in the clinic, often with neutral and sometimes even detrimental outcomes. Recently, drug development has focused, instead, on identifying and selectively modulating ROS enzymatic sources that in a given constellation cause disease while leaving ROS physiologic signaling and metabolic functions intact. As sources, the family of NADPH oxidases stands out as the only enzyme family solely dedicated to ROS formation. Selectively targeting disease-relevant ROS-related proteins is already quite advanced, as evidenced by several phase II/III clinical trials and the first drugs having passed registration. The ROS field is expanding by including target enzymes and maturing to resemble more and more modern, big data–enhanced drug discovery and development, including network pharmacology. By defining a disease based on a distinct mechanism, in this case ROS dysregulation, and not by a symptom or phenotype anymore, ROS pharmacology is leaping forward from a clinical underperformer to a proof of concept within the new era of mechanism-based precision medicine., This study was supported by the European Research Council Advanced Investigator Grant/RadMed [Grant 294683], Proof-of-Concept Grant/SAVEBRAIN [Grant 737586], and H2020 Project REPO-TRIAL [Grant 777111] (to H.H.H.W.S.) and short-term scientific missions by the COST Actions EU-ROS and Open-MultiMed, and Kootstra Talented Fellowship (Maastricht University) (to A.I.C.)., Peer reviewed